Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Libbs Farmaceutica LtdafiledCriticalLibbs Farmaceutica Ltda
Publication of BRPI0418963ApublicationCriticalpatent/BRPI0418963A/en
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
BRPI0418963-9A2004-07-202004-07-20 localized fat reduction composition, use of pharmaceutically acceptable surfactant compounds and methods for localized fat reductionBRPI0418963A (en)
DERIVATIVES OF 2,3-DIHYDROIMIDAZOL [1,2-C] QUINAZOLINE SUBSTITUTED FOR USEFULNESS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
Use of a combination of an anti-angiogenic agent and an antihypertensive agent, kit for use in producing an anti-angiogenic effect and / or vascular permeability reducing effect in a warm-blooded animal, and method of treating a unhealthy state associated with angiogenesis